Carregant...

Development of ‘DFG-out’ inhibitors of gatekeeper mutant kinases

HG-7-85-01(22) and HG-7-86-01(26) are thiazolo[5,4-b]pyridine containing type II tyrosine kinase inhibitors with potent cellular activity against both wild-type and ‘gatekeeper’ mutant T315I- Bcr-Abl. Here we report on the ‘hybrid design’ concept and subsequent structure activity guided optimization...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Choi, Hwan Geun, Zhang, Jianming, Weisberg, Ellen, Griffin, James D., Sim, Taebo, Gray, Nathanael S.
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3415686/
https://ncbi.nlm.nih.gov/pubmed/22819762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bmcl.2012.06.036
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!